Anticancer activity of Helicobacter pylori ribosomal protein (HPRP) with iRGD in treatment of colon cancer

Yaghoubi, Atieh; Asgharzadeh, Fereshteh; Movaqar, Aref; Ghazvini, Kiarash; Hassanian, Seyed Mahdi; Avan, Amir; Soleimanpour, Saman

doi:10.1007/s00432-021-03683-7

Cited by 4 publications

(5 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coadministration with small‐molecule inhibitors (Fadeev et al, 2019; Schmithals et al, 2015). Coadministration with therapeutic antibodies or peptides (Hu et al, 2018a; Sugahara et al, 2010; Yaghoubi et al, 2021; Y. Zhang, Yang, et al, 2016). Coadministration with nanoparticles (Deng et al, 2018; X. Liu, Lin, et al, 2017).…”

Section: Drug Delivery Methods Of Irgdmentioning

confidence: 99%

“…(3) Coadministration with therapeutic antibodies or peptides (Hu et al, 2018a;Sugahara et al, 2010;Yaghoubi et al, 2021;Y. Zhang, Yang, et al, 2016).…”

Section: Drug Delivery Methods Of Irgdmentioning

confidence: 99%

“…Coadministration of the iRGD peptide improved the anticancer efficacy of the therapeutic antibodies trastuzumab (Sugahara et al, 2010) and cetuximab (Y. Zhang, Yang, et al, 2016), suggesting that iRGD may serve as a new clinical application approach for adjuvant therapeutic antibodies. Moreover, when HPRP‐A1 and iRGD were coadministered, the iRGD peptide significantly increased the depth of HPRP‐A1 penetration into the tumor (Hu et al, 2018a; Yaghoubi et al, 2021) and increasing the production of reactive oxygen species (ROS) to induce cell apoptosis, thereby considerably suppressing tumor growth (Yaghoubi et al, 2021).…”

Section: Irgd Delivers Recombinant Proteins and Peptidesmentioning

confidence: 99%

See 2 more Smart Citations

Recent advances in the tumor‐penetrating peptide internalizing RGD for cancer treatment and diagnosis

Qian

Zhou

Lin

et al. 2023

Drug Development Research

View full text Add to dashboard Cite

Cancer has become a prominent disease that seriously endangers human health. The complexity of the biological characteristics of the tumor makes it challenging for traditional therapeutic drugs to penetrate tumor tissues and exert their antitumor effects. Internalizing RGD peptide (iRGD) is a novel tumor‐homing peptide that binds to αvβ3 and αvβ5 integrins on the surface of tumor vessels through the C‐end rule (CendR) motif. The CendR motif binds to the neuropilin‐1 (NRP‐1) receptor on tumor cells, initiating NRP‐1‐mediated transcytosis to facilitate drug entry into the tumor tissue. Multiple studies demonstrated that iRGD improved the penetration and targeting of antitumor drugs, thereby enhancing their antitumor efficacy. In this review, we initially described the origins of iRGD and its penetration mechanism. Furthermore, we presented updates on the application of iRGD in cancer chemotherapy, photodynamic therapy, gene therapy, immunotherapy, treatment with antibodies or protein‐based biologics, and tumor imaging.

show abstract

Section: Drug Delivery Methods Of Irgdmentioning

confidence: 99%

“…(3) Coadministration with therapeutic antibodies or peptides (Hu et al, 2018a;Sugahara et al, 2010;Yaghoubi et al, 2021;Y. Zhang, Yang, et al, 2016).…”

Section: Drug Delivery Methods Of Irgdmentioning

confidence: 99%

Section: Irgd Delivers Recombinant Proteins and Peptidesmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in the tumor‐penetrating peptide internalizing RGD for cancer treatment and diagnosis

Qian

Zhou

Lin

et al. 2023

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…Nevertheless, because of their different origins, these cell lines exhibit various genetic and epigenetic changes as well as mutations due to their diverse origins. Efficacy/cytotoxicity studies on both cell lines indicate that cells respond differently to the treated groups [61][62][63].…”

Section: Evaluation Of Anticancer Efficiency Of Cpt-loaded Nanopartic...mentioning

confidence: 99%

Insight into oral amphiphilic cyclodextrin nanoparticles for colorectal cancer: comprehensive mathematical model of drug release kinetic studies and antitumoral efficacy in 3D spheroid colon tumors

Ünal¹,

Varan²,

Benito³

et al. 2023

Beilstein J. Org. Chem.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most diagnosed cancer type globally and ranks second in cancer-related deaths. With the current treatment possibilities, a definitive, safe, and effective treatment approach for CRC has not been presented yet. However, new drug delivery systems show promise in this field. Amphiphilic cyclodextrin-based nanocarriers are innovative and interesting formulation approaches for targeting the colon through oral administration. In our previous studies, oral chemotherapy for colon tumors was aimed and promising results were obtained with formulation development studies, mucin interaction, mucus penetration, cytotoxicity, and permeability in 2D cell culture, and furthermore in vivo antitumoral and antimetastatic efficacy in early and late-stage colon cancer models and biodistribution after single dose oral administration. This study was carried out to further elucidate oral camptothecin (CPT)-loaded amphiphilic cyclodextrin nanoparticles for the local treatment of colorectal tumors in terms of their drug release behavior and efficacy in 3-dimensional tumor models to predict the in vivo efficacy of different nanocarriers. The main objective was to build a bridge between formulation development and in vitro phase and animal studies. In this context, CPT-loaded polycationic-β-cyclodextrin nanoparticles caused reduced cell viability in CT26 and HT29 colon carcinoma spheroid tumors of mice and human origin, respectively. In addition, the release profile, which is one of the critical quality parameters in new drug delivery systems, was investigated mathematically by release kinetic modeling for the first time. The overall findings indicated that the strategy of orally targeting anticancer drugs such as CPT with positively charged poly-β-CD-C6 nanoparticles to colon tumors for local and/or systemic efficacy is a promising approach.

show abstract

“…While the Helicobacter spp. have mainly been investigated for their pro‐tumorigenic properties, one study suggests that a ribosomal protein of H. pylori has anti‐tumorigenic activity by increasing p53 gene expression and apoptosis in in vitro models and by reducing tumor growth in an isograft mouse model when co‐administered with 5‐fluorouracil and tumor‐homing peptide iRGD [92].…”

Section: Carcinoma (Egfr Mtor and P53)mentioning

confidence: 99%

The gut microbiota can orchestrate the signaling pathways in colorectal cancer

Bennedsen

Furbo

Bjarnsholt

et al. 2022

APMIS

View full text Add to dashboard Cite

Current evidence suggests that bacteria contribute to the development of certain cancers, such as colorectal cancer (CRC), partly by stimulating chronic inflammation. However, little is known about the bacterial impact on molecular pathways in CRC. Recent studies have demonstrated how specific bacteria can influence the major CRC‐related pathways, i.e., Wnt, PI3K‐Akt, MAPK, TGF‐β, EGFR, mTOR, and p53. In order to advance the current understanding and facilitate the choice of pathways to investigate, we have systematically collected and summarized the current knowledge within bacterial altered major pathways in CRC. Several pro‐tumorigenic and anti‐tumorigenic bacterial species and their respective metabolites interfere with the major signaling pathways addressed in this review. Not surprisingly, some of these studies investigated known CRC drivers, such as Escherichia coli, Fusobacterium nucleatum, and Bacteroides fragilis. Interestingly, some metabolites produced by bacterial species typically considered pathogenic, e.g., Vibrio cholera, displayed anti‐tumorigenic activities, emphasizing the caution needed when classifying healthy and unhealthy microorganisms. The results collectively emphasize the complexity of the relationship between the microbiota and the tumorigenesis of CRC, and future studies should verify these findings in more realistic models, such as organoids, which constitute a promising platform. Moreover, future trials should investigate the clinical potential of preventive modulation of the gut microbiota regarding CRC development.

show abstract

Anticancer activity of Helicobacter pylori ribosomal protein (HPRP) with iRGD in treatment of colon cancer

Cited by 4 publications

References 47 publications

Recent advances in the tumor‐penetrating peptide internalizing RGD for cancer treatment and diagnosis

Recent advances in the tumor‐penetrating peptide internalizing RGD for cancer treatment and diagnosis

Insight into oral amphiphilic cyclodextrin nanoparticles for colorectal cancer: comprehensive mathematical model of drug release kinetic studies and antitumoral efficacy in 3D spheroid colon tumors

The gut microbiota can orchestrate the signaling pathways in colorectal cancer

Contact Info

Product

Resources

About